Date: 2013-05-20
Type of information: Company acquisition
Acquired company: AOP Orphan (Austria)
Acquiring company: Elan (Ireland)
Amount: €263.5 million
Terms: * On May 20, 2013, Elan has announced a series of transactions designed to transform and advance the company. Elan will acquire 100% of AOP Orphan Pharmaceuticals (AOP) and upon close Elan will pay €263.5million for the company, comprised of €175.7 million in cash and €87.8 million of Elan ordinary shares. In addition, there will be potential cash milestone payments of up to €270 million on the advancement (filing and acceptance) of certain late stage clinical programs.
Details: AOP Orphan has been founded in 1996 by Dr. Rudolf Widmann (formerly GSK/Wellcome). The company has four late stage pipeline programs (2014-2018 time frame) in: Hematology/Oncology and Cardiology/Pulmonology indications.
Related: Rare diseases
